Published in J Clin Oncol on July 01, 1998
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis (2013) 1.49
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother (2011) 1.18
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax (2002) 1.16
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer (2006) 1.05
Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer (2002) 1.00
Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol (2003) 0.98
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics (2009) 0.95
Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. Korean J Intern Med (2010) 0.94
Vinorelbine--a clinical review. Br J Cancer (2000) 0.93
Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res (2010) 0.90
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer (2007) 0.88
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer (2005) 0.86
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res (2013) 0.86
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation? J Oncol Pract (2012) 0.85
Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol (2011) 0.85
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer (2008) 0.84
Preclinical Murine Models for Lung Cancer: Clinical Trial Applications. Biomed Res Int (2015) 0.83
Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet Genomics (2012) 0.83
Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer (2013) 0.82
Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib. Br J Cancer (2004) 0.82
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer. Br J Cancer (2003) 0.80
Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer (2012) 0.80
Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study. Br J Cancer (2002) 0.79
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer (2007) 0.78
An increase in glucosylceramide synthase induces Bcl-xL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells. Oncotarget (2015) 0.77
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer (2000) 0.76
Comparison of vinorelbine-Cisplatin with gemcitabine-Cisplatin in patients with advanced non-small cell lung cancer. Clin Med Circ Respirat Pulm Med (2008) 0.76
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. Core Evid (2007) 0.75
A phase II study of vinorelbine, mitomycin C and cisplatin chemotherapy for advanced non-small cell lung cancer. Korean J Intern Med (2002) 0.75
Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial. Onco Targets Ther (2017) 0.75
Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. Onco Targets Ther (2009) 0.75
Chemotherapy of advanced non-small-cell lung cancer: "Those who cannot remember the past are condemned to repeat it". J Clin Oncol (1999) 0.75
Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). BMC Cancer (2004) 0.75
Refining the treatment of advanced nonsmall cell lung cancer. Lung Cancer (Auckl) (2010) 0.75
Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer. Int J Clin Oncol (2012) 0.75
Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer. Invest New Drugs (2007) 0.75
Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. Int J Clin Oncol (2006) 0.75
Chemotherapy in non-small cell lung cancer. Invest New Drugs (2000) 0.75
Venous damage prevention by defibrotide in vinorelbine-treated patients. Support Care Cancer (2003) 0.75
Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell (1983) 17.87
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol (2001) 6.83
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med (1999) 5.84
Recruitment of p300/CBP in p53-dependent signal pathways. Cell (1997) 5.10
Breast Cancer Detection Demonstration Project: five-year summary report. CA Cancer J Clin (1982) 4.90
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
Cloning of a mitogen-inducible gene encoding a kappa B DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs. Nature (1990) 4.61
Functional role for c-myc in mitogenic response to platelet-derived growth factor. Nature (1984) 4.56
Evaluation of cancer information on the Internet. Cancer (1999) 4.55
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med (2000) 4.54
Negative transport & resistance to water flow through plants. Plant Physiol (1961) 4.10
Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res (1977) 4.02
A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site. Mol Cell Biol (1992) 3.63
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol (2001) 3.06
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol (1991) 3.01
The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature (1992) 2.95
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol (1995) 2.89
A general method for the detection of large CAG repeat expansions by fluorescent PCR. J Med Genet (1996) 2.83
PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science (1993) 2.80
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73
Measurement of iron stores using deferoxamine. Ann Intern Med (1968) 2.69
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol (1986) 2.64
The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem (1996) 2.60
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer (1989) 2.43
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol (2007) 2.43
The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol (1978) 2.43
Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys (1993) 2.42
Complexity of the primary genetic response to mitogenic activation of human T cells. Mol Cell Biol (1989) 2.40
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol (2000) 2.39
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature (1994) 2.24
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs (1992) 2.22
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res (2000) 2.14
Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. Oncogene (1992) 2.13
Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax (1992) 2.11
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 2.10
Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet (1992) 2.08
Effects of a physician communication intervention on patient care outcomes. J Gen Intern Med (1996) 2.06
Prophylactic cranial irradiation for patients with small-cell lung cancer. J Natl Cancer Inst (1995) 2.05
Propofol and convulsions--the evidence mounts. Anaesth Intensive Care (1991) 2.04
Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer (1978) 2.04
An association between the common hereditary hemochromatosis mutation and the factor V Leiden allele in a population with thrombosis. Blood (1998) 2.03
De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat Genet (1993) 2.02
Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule. Arch Dis Child (1992) 2.02
Nested case-control study of selected systemic autoimmune diseases in World Trade Center rescue/recovery workers. Arthritis Rheumatol (2015) 2.02
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol (1995) 1.96
Effects of corticosteroid therapy on human monocyte function. N Engl J Med (1975) 1.96
Gem: an induced, immediate early protein belonging to the Ras family. Science (1994) 1.94
Immune protection and control of inflammatory tissue necrosis by gamma delta T cells. J Immunol (1994) 1.92
The regulation and expression of c-myc in normal and malignant cells. Annu Rev Immunol (1986) 1.90
Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer (1975) 1.84
Developmental status and reconstitution potential of subpopulations of murine thymocytes. Immunol Rev (1988) 1.82
Effects of reinforcement on standardized test performance. J Appl Behav Anal (1972) 1.82
Effects of corticosteroids on human monocyte function. J Clin Invest (1974) 1.81
Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer (1991) 1.78
Assessing community readiness for prevention. Int J Addict (1995) 1.76
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol (1994) 1.76
A novel alteration in the structure of an activated c-myc gene in a variant t(2;8) Burkitt lymphoma. Cell (1984) 1.74
MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene (2012) 1.73
Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest (1991) 1.72
Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis (2013) 1.67
Adriamycin cardiotoxicity in man. Ann Intern Med (1974) 1.66
The Cincinnati Lipid Research Clinic family study: cultural and biological determinants of lipids and lipoprotein concentrations. Am J Hum Genet (1982) 1.64
Comparative mapping between Medicago sativa and Pisum sativum. Mol Genet Genomics (2004) 1.63
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Diabetes self-management. Self-reported recommendations and patterns in a large population. Diabetes Care (1997) 1.59
Chronic intracochlear electrical stimulation in the neonatally deafened cat. I: Expansion of central representation. Hear Res (1990) 1.58
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol (1990) 1.57
Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest (1995) 1.56
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst (2001) 1.55
Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med (1993) 1.55
The F plasmid origin of transfer: DNA sequence of wild-type and mutant origins and location of origin-specific nicks. EMBO J (1984) 1.54
Two distinct mechanisms of transcriptional control operate on c-myc during differentiation of HL60 cells. Mol Cell Biol (1988) 1.51
Dose response evaluation of adriamycin in human neoplasia. Cancer (1977) 1.51
Reactivity to alcohol-related cues: physiological and subjective responses in alcoholics and nonproblem drinkers. J Stud Alcohol (1985) 1.50
Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut (2005) 1.49
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci (1989) 1.48
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol (1998) 1.48
Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynaecol (1992) 1.47
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med (1988) 1.46
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Bone morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells. J Cell Biochem (1995) 1.45
Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry (1989) 1.45
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res (1998) 1.44